Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Hypersensitivity Reaction

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 61 articles: HTML format

Single Articles

October 2025
1. BAUGHMAN RP, Grutters JC, Lower EE, Zhou Y, et al
   Pulmonary sarcoidosis clinical trial end-points: a Delphi study.
   Eur Respir J. 2025;66:2500943.
   PubMed     Abstract available
   
   
   June 2025
2. SHENG-KAI MA K, Brumbaugh B, Saff RR, Phipatanakul W, et al
   Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study.
   Eur Respir J. 2025 Jun 19:2500139. doi: 10.1183/13993003.00139-2025.
   PubMed     Abstract available
   
   
   
3. HE D, Guler SA, Shannon CP, Ryerson CJ, et al
   Transcriptomics of interstitial lung disease: a systematic review and meta-analysis.
   Eur Respir J. 2025;65:2401070.
   PubMed     Abstract available
   
   
   April 2025
4. AGARWAL R, Sehgal IS, Muthu V, Denning DW, et al
   Reply: Perspectives on high-attenuation mucus, CT and MRI in allergic bronchopulmonary aspergillosis.
   Eur Respir J. 2025;65:2500196.
   PubMed    
   
   
   
5. DOURNES G, Benlala I, Berger P
   2024 imaging criteria for allergic bronchopulmonary aspergillosis: which diagnostic cut-offs? Are chest radiograph and CT comparable?
   Eur Respir J. 2025;65:2500089.
   PubMed    
   
   
   February 2025
6. CELIS-PRECIADO C, Leclerc S, Duval M, Cliche DO, et al
   Phenotyping the Responses to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA).
   Eur Respir J. 2025 Feb 13:2402391. doi: 10.1183/13993003.02391-2024.
   PubMed     Abstract available
   
   
   January 2025
7. DEITEREN A, Krupka E, Bontinck L, Imberdis K, et al
   A proof-of-mechanism trial in asthma with lunsekimig, a bispecific nanobody(R) molecule.
   Eur Respir J. 2025 Jan 30:2401461. doi: 10.1183/13993003.01461-2024.
   PubMed     Abstract available
   
   
   
8. SOENDERGAARD MB, Hjortdahl F, Hansen S, Bjerrum AS, et al
   Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma.
   Eur Respir J. 2025 Jan 9:2401497. doi: 10.1183/13993003.01497-2024.
   PubMed     Abstract available
   
   
   December 2024
9. ARKEMA EV, Sachs MC, Dominicus A, Eklund A, et al
   Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case-control study in Sweden.
   Eur Respir J. 2024;64:2400277.
   PubMed     Abstract available
   
   
   November 2024
10. KHALEVA E, Brightling C, Eiwegger T, Altraja A, et al
    Patient-centred composite scores as tools for assesment of response to biological therapy for paediatric and adult severe asthma.
    Eur Respir J. 2024 Nov 7:2400691. doi: 10.1183/13993003.00691-2024.
    PubMed     Abstract available
    
    
    
11. JAGGI TK, Agarwal R, Tiew PY, Shah A, et al
    Fungal lung disease.
    Eur Respir J. 2024;64:2400803.
    PubMed     Abstract available
    
    
    October 2024
12. KERMANI NZ, Chung KF, Macis G, Santini G, et al
    Radiomultiomics: quantitative CT clusters of severe asthma associated with multi-omics.
    Eur Respir J. 2024 Oct 10:2400207. doi: 10.1183/13993003.00207-2024.
    PubMed     Abstract available
    
    
    
13. HAMADA Y, Thomas D, Harvey ES, Stevens S, et al
    Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma.
    Eur Respir J. 2024 Oct 10:2400782. doi: 10.1183/13993003.00782-2024.
    PubMed     Abstract available
    
    
    
14. MCSORLEY HJ
    RIPK2 inhibition gets the NOD for asthma.
    Eur Respir J. 2024;64:2401372.
    PubMed    
    
    
    September 2024
15. WECHSLER ME, Brusselle G, Virchow JC, Bourdin A, et al
    Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.
    Eur Respir J. 2024 Sep 26:2400316. doi: 10.1183/13993003.00316-2024.
    PubMed     Abstract available
    
    
    
16. ZHU Z, Shibata R, Hoffman KL, Cormier J, et al
    Integrated nasopharyngeal airway metagenome and asthma genetic risk endotyping of severe bronchiolitis in infancy and risk of childhood asthma.
    Eur Respir J. 2024 Sep 26:2401130. doi: 10.1183/13993003.01130-2024.
    PubMed     Abstract available
    
    
    
17. GIBSON PG, McDonald VM
    Integrating hot topics and implementation of treatable traits in asthma.
    Eur Respir J. 2024 Sep 10:2400861. doi: 10.1183/13993003.00861-2024.
    PubMed     Abstract available
    
    
    
18. LAHOUSSE L
    Overweight and dysanapsis in childhood asthma.
    Eur Respir J. 2024;64:2401164.
    PubMed    
    
    
    
19. MAKRINIOTI H, Fainardi V, Bonnelykke K, Custovic A, et al
    European Respiratory Society statement on preschool wheezing disorders: updated definitions, knowledge gaps and proposed future research directions.
    Eur Respir J. 2024;64:2400624.
    PubMed     Abstract available
    
    
    
20. WENZEL SE
    Allergen challenge, eosinophils and the long road to asthma endotypes.
    Eur Respir J. 2024;64:2401316.
    PubMed    
    
    
    August 2024
21. VERSI A, Azim A, Ivan FX, Abdel-Aziz MI, et al
    Host-microbial interactions differ with age of asthma onset.
    Eur Respir J. 2024 Aug 30:2400428. doi: 10.1183/13993003.00428-2024.
    PubMed    
    
    
    
22. ABDO M, Pedersen F, Kirsten AM, Trinkmann F, et al
    Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD.
    Eur Respir J. 2024 Aug 15:2400347. doi: 10.1183/13993003.00347-2024.
    PubMed    
    
    
    
23. AILI A, Wang Y, Shang Y, Zhang L, et al
    LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T cells.
    Eur Respir J. 2024 Aug 15:2301752. doi: 10.1183/13993003.01752-2023.
    PubMed     Abstract available
    
    
    
24. ALVAREZ-SIMON D, Ait Yahia S, Audousset C, Fanton d'Andon M, et al
    Local Receptor-interacting Protein Kinase 2 inhibition mitigates HDM-induced asthma.
    Eur Respir J. 2024 Aug 8:2302288. doi: 10.1183/13993003.02288-2023.
    PubMed     Abstract available
    
    
    
25. BLOOM C
    The burden of zoster in asthma: what is left to learn?
    Eur Respir J. 2024;64:2401300.
    PubMed    
    
    
    
26. KHURANA S, Georas SN
    Stepping down biologics in asthma: is it time to challenge the status quo?
    Eur Respir J. 2024;64:2401168.
    PubMed    
    
    
    July 2024
27. GAUVREAU GM, Sehmi R, FitzGerald JM, Leigh R, et al
    Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled, trial.
    Eur Respir J. 2024 Jul 26:2400512. doi: 10.1183/13993003.00512-2024.
    PubMed     Abstract available
    
    
    
28. WILKINSON A, Woodcock A
    High-quality and low-carbon asthma care go hand in hand.
    Eur Respir J. 2024;64:2400638.
    PubMed    
    
    
    
29. SOUMAGNE T, Degano B
    Real world evidence in asthma: what to expect beyond randomised controlled trials?
    Eur Respir J. 2024;64:2400716.
    PubMed    
    
    
    
30. LU J, Wang Z
    Mendelian randomisation supports no evidence of the association between asthma and coronary heart disease in East Asians.
    Eur Respir J. 2024;64:2400628.
    PubMed    
    
    
    June 2024
31. MORTIMER KJ, Cruz AA, Sepulveda-Pachon IT, Jorga A, et al
    Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis.
    Eur Respir J. 2024 Jun 20:2400462. doi: 10.1183/13993003.00462-2024.
    PubMed     Abstract available
    
    
    
32. STIKKER B, Trap L, Sedaghati-Khayat B, de Bruijn MJW, et al
    Epigenomic partitioning of a polygenic risk score for asthma reveals distinct genetically driven disease pathways.
    Eur Respir J. 2024 Jun 20:2302059. doi: 10.1183/13993003.02059-2023.
    PubMed     Abstract available
    
    
    
33. SAIKUMAR JAYALATHA AK, Ketelaar ME, Hesse L, Badi YE, et al
    IL-33 induced gene expression in activated Th2 effector cells is dependent on IL-1RL1 haplotype and asthma status.
    Eur Respir J. 2024 Jun 6:2400005. doi: 10.1183/13993003.00005-2024.
    PubMed    
    
    
    
34. VERBANCK S, Eddy RL, McIntosh MJ, Parraga G, et al
    Missing airways, ventilation defects and conductive airway physiology in asthma.
    Eur Respir J. 2024 Jun 6:2400242. doi: 10.1183/13993003.00242-2024.
    PubMed    
    
    
    
35. SOENDERGAARD MB, Bjerrum AS, Rasmussen LM, Lock-Johansson S, et al
    OPTIMAL: Titration of anti-IL5 biologics in severe asthma - An open label randomised controlled trial.
    Eur Respir J. 2024 Jun 6:2400404. doi: 10.1183/13993003.00404-2024.
    PubMed     Abstract available
    
    
    
36. MCDOWELL PJ, McDowell R, Busby J, Eastwood MC, et al
    Clinical remission with biologic therapies in severe asthma: a matter of definition.
    Eur Respir J. 2024;63:2400160.
    PubMed     Abstract available
    
    
    
37. BEASLEY R, Noble J, Weatherall M
    The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma.
    Eur Respir J. 2024;63:2400523.
    PubMed     Abstract available
    
    
    
38. SUOJALEHTO H, Charles-Poucel S, Suuronen K, Ronsmans S, et al
    Presenting clinical data for the hazard classification of chemical respiratory sensitisers.
    Eur Respir J. 2024;63:2400338.
    PubMed    
    
    
    May 2024
39. KJELDGAARD JENSEN S, Tingskov Pedersen CE, Fischer-Rasmussen K, Elsner Melgaard M, et al
    Genetic predisposition to high BMI increases risk of early life respiratory infections and episodes of severe wheeze and asthma.
    Eur Respir J. 2024 May 29:2400169. doi: 10.1183/13993003.00169-2024.
    PubMed     Abstract available
    
    
    
40. LIU T, Prescott WG, Zhou X
    Advances in Non-Type 2 Asthma in the Severe Cases: from molecular insights to novel treatment strategies.
    Eur Respir J. 2024 May 2:2300826. doi: 10.1183/13993003.00826-2023.
    PubMed     Abstract available
    
    
    
41. MOSS RB
    T-cells and precision medicine for allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024;63:2400549.
    PubMed    
    
    
    
42. RAMAKRISHNAN S, Montgomery B, Pavord ID
    Blood eosinophils and lung function loss: from passive prediction to active prevention?
    Eur Respir J. 2024;63:2400812.
    PubMed    
    
    
    
43. BUSH A, Randerath W, Roche N
    As needed ICS/formoterol: not all of Europe is equal.
    Eur Respir J. 2024;63:2400408.
    PubMed    
    
    
    
44. HONG YS, Park HY, Ryu S, Shin SH, et al
    The association of blood eosinophil counts and FEV(1) decline: a cohort study.
    Eur Respir J. 2024;63:2301037.
    PubMed     Abstract available
    
    
    
45. POLVERINO F, Sin DD
    Type 2 airway inflammation in COPD.
    Eur Respir J. 2024;63:2400150.
    PubMed     Abstract available
    
    
    April 2024
46. HATTER L, Holliday M, Eathorne A, Bruce P, et al
    The carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis.
    Eur Respir J. 2024 Apr 12:2301705. doi: 10.1183/13993003.01705-2023.
    PubMed     Abstract available
    
    
    
47. JACKSON DJ, Pelaia G, Emmanuel B, Tran TN, et al
    Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
    Eur Respir J. 2024 Apr 4:2301521. doi: 10.1183/13993003.01521-2023.
    PubMed     Abstract available
    
    
    
48. KRISHNAN JA, Buhl R
    As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2302308.
    PubMed    
    
    
    
49. PAPI A, Ferreira DS, Tonia T, Schleich F, et al
    Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2400395.
    PubMed    
    
    
    
50. 
    ERJ Podcast April 2024: Allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024;63:24E6304.
    PubMed    
    
    
    
51. BLOOM CI
    Reply: Asthma and cardiovascular disease: the strength of triangulation.
    Eur Respir J. 2024;63:2400554.
    PubMed    
    
    
    
52. TATTERSALL MC, Gangnon RE, Jarjour NN
    Asthma and cardiovascular disease: embracing disease heterogeneity is required.
    Eur Respir J. 2024;63:2400469.
    PubMed    
    
    
    
53. STANESCU C, Talarico R, Weichenthal S, Villeneuve PJ, et al
    Early life exposure to pollens and increased risks of childhood asthma: a prospective cohort study in Ontario children.
    Eur Respir J. 2024;63:2301568.
    PubMed     Abstract available
    
    
    
54. VARRICCHI G, Brightling CE, Grainge C, Lambrecht BN, et al
    Airway remodelling in asthma and the epithelium: on the edge of a new era.
    Eur Respir J. 2024;63:2301619.
    PubMed     Abstract available
    
    
    March 2024
55. LUO RG, Wu YF, Lu HW, Weng D, et al
    Th2-skewed peripheral T helper cells drives B cells in allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024 Mar 21:2400386. doi: 10.1183/13993003.00386-2024.
    PubMed     Abstract available
    
    
    
56. LIU T, Liu S, Rui X, Cao Y, et al
    Gasdermin B, an asthma-susceptibility gene, promotes MAVS-TBK1 signaling and airway inflammation.
    Eur Respir J. 2024 Mar 21:2301232. doi: 10.1183/13993003.01232-2023.
    PubMed     Abstract available
    
    
    
57. RUSSELL RJ, Boulet LP, Brightling CE, Pavord ID, et al
    The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
    Eur Respir J. 2024 Mar 7:2301397. doi: 10.1183/13993003.01397-2023.
    PubMed     Abstract available
    
    
    February 2024
58. AGARWAL R, Singh Sehgal I, Muthu V, Denning DW, et al
    Revised clinical practice guidelines for diagnosing, classifying, and treating allergic bronchopulmonary aspergillosis/mycoses: a Delphi statement from the ISHAM-ABPA working group.
    Eur Respir J. 2024 Feb 29:2400061. doi: 10.1183/13993003.00061-2024.
    PubMed     Abstract available
    
    
    
59. WANG T, Duan W, Jia X, Huang X, et al
    Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.
    Eur Respir J. 2024;63:2301720.
    PubMed     Abstract available
    
    
    September 2023
60. PAPI A, Ferreira DS, Agache I, Baraldi E, et al
    European Respiratory Society Short Guidelines for the use of as-needed ICS/formoterol in mild Asthma.
    Eur Respir J. 2023 Sep 7:2300047. doi: 10.1183/13993003.00047-2023.
    PubMed     Abstract available
    
    
    August 2023
61. 
    ERJ Podcast August 2024: Titration of anti-IL-5 biologics in severe asthma.
    Eur Respir J. 2024;64:24E6402.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hypersensitivity Reaction is free of charge.